Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL). Despite this, treatment challenges remain, particularly in patients with high-risk disease. This Velocity Vlog activity featuring Dr. John N. Allan addresses the question of how to integrate the latest knowledge into clinical practice to help guide treatment choices for patients with high-risk CLL.
Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CLL
© 2018 Imedex, LLC.